Key facts
- Slope (Healthcare Technology Systems)’s last known valuation is $89.0M.
- It has raised $37.9M; the latest was Later Stage VC ($14.0M) in Aug 2024.
- Notable investors include Alumni Ventures, New Enterprise Associates, GrowthX Capital, Breyer Capital, Eniac Ventures — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Slope (Healthcare Technology Systems)
- ·The full record, as it builds
Funding rounds
No funding rounds for Slope (Healthcare Technology Systems) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Slope (Healthcare Technology Systems)
Provider of biospecimen lifecycle software, data, and services for clinical trials. The company's core offering, Biospecimen360™ (B360™), is a vendor-agnostic software that orchestrates the entire biospecimen lifecycle, enabling bi-directional data exchange across sites, labs, LIMS, and EDC, as well as centralized sample tracking.
- Sector
- Healthcare
- HQ
- Norfolk, VA, United States
- Founded
- 2016
- Employees
- 57
- Website
- slopeclinical.com/
- Ownership
- Privately Held (backing)
Slope (Healthcare Technology Systems) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Slope (Healthcare Technology Systems) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Slope (Healthcare Technology Systems) in its N-PORT filings yet. We sweep new filings monthly.